Revolution Medicines (RVMD.US) announced positive results from a Phase 1b clinical trial of its broad-spectrum RAS inhibitor, RMC-6236.
AInvestMonday, Jul 15, 2024 11:10 pm ET
1min read
RVMD --

Revolution Medicines (RVMD.US) announced positive results from its Phase 1b clinical trial of its pan-RAS inhibitor RMC-6236. Analysis showed that RMC-6236 as a single agent prolonged median progression-free survival (PFS) to 8.1 months and achieved near 90% disease control rate (DCR) in patients with KRAS G12X mutation. KRAS G12X refers to the conversion of glycine at residue 12 of the KRAS protein to another amino acid due to a genetic mutation. The Company is preparing to initiate a global randomized Phase 3 trial of the drug as a pipeline therapy for patients with PDAC.

According to Revolution Medicines, RMC-6236 is the first-in-class targeted therapy for all major RAS mutant cancers. RAS mutations are the major driver of PDAC disease progression.

Cancer cells driven by RAS mutations account for up to 30% of all human cancers, most notably in PDAC, NSCLC and CRC. RMC-6236 is an oral, selective inhibitor of mutant and wild-type RAS in the GTP-bound (active, ON) state.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.